Centessa Pharmaceuticals plc (ADR)
General ticker "CNTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.3B (TTM average)
Centessa Pharmaceuticals plc (ADR) follows the US Stock Market performance with the rate: 50.8%.
Estimated limits based on current volatility of 0.2%: low 39.44$, high 39.57$
Factors to consider:
- Total employees count: 76 (-8.4%) as of 2023
- Top business risk factors: Labor/talent shortage/retention, Operational and conduct risks, Regulatory and compliance, Supply chain disruptions, Economic downturns and volatility
- Current price 19.4% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.30$, 33.23$]
- 2026-12-31 to 2027-12-31 estimated range: [14.06$, 28.26$]
Financial Metrics affecting the CNTA estimates:
- Negative: with PPE of -17.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.69 <= 0.07
- Positive: Interest expense per share per price, % of 0.34 <= 0.73
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Positive: Shareholder equity ratio, % of 76.64 > 64.25
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CNTA quotes
Long-term CNTA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6.85MM | $0.00MM | $15.00MM |
| Operating Expenses | $178.14MM | $201.06MM | $222.69MM |
| Operating Income | $-171.28MM | $-201.06MM | $-207.69MM |
| Non-Operating Income | $-4.86MM | $-31.86MM | $11.98MM |
| Interest Expense | $9.91MM | $10.09MM | $11.46MM |
| R&D Expense | $124.41MM | $150.24MM | $172.22MM |
| Income(Loss) | $-176.14MM | $-232.91MM | $-195.71MM |
| Taxes | $-25.06MM | $2.84MM | $1.82MM |
| Profit(Loss)* | $-151.09MM | $-235.76MM | $-197.53MM |
| Stockholders Equity | $236.24MM | $401.55MM | $526.86MM |
| Assets | $360.25MM | $576.80MM | $687.50MM |
| Operating Cash Flow | $-160.34MM | $-142.06MM | $-193.82MM |
| Capital expenditure | $0.17MM | $0.03MM | $0.37MM |
| Investing Cash Flow | $-127.00MM | $31.27MM | $-418.53MM |
| Financing Cash Flow | $21.12MM | $364.75MM | $291.53MM |
| Earnings Per Share** | $-1.57 | $-2.06 | $-1.46 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.